247 related articles for article (PubMed ID: 31685417)
1. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies.
Jasim S; Jimenez C
Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101354. PubMed ID: 31685417
[TBL] [Abstract][Full Text] [Related]
2. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.
Ilanchezhian M; Jha A; Pacak K; Del Rivero J
Curr Treat Options Oncol; 2020 Aug; 21(11):85. PubMed ID: 32862332
[TBL] [Abstract][Full Text] [Related]
3. Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management.
Hamidi O
Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):146-154. PubMed ID: 30893083
[TBL] [Abstract][Full Text] [Related]
4. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
[TBL] [Abstract][Full Text] [Related]
5. Malignant pheochromocytoma and paraganglioma: management options.
Corssmit EPM; Snel M; Kapiteijn E
Curr Opin Oncol; 2020 Jan; 32(1):20-26. PubMed ID: 31599769
[TBL] [Abstract][Full Text] [Related]
6. Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.
Jimenez P; Tatsui C; Jessop A; Thosani S; Jimenez C
Curr Oncol Rep; 2017 Oct; 19(12):83. PubMed ID: 29081018
[TBL] [Abstract][Full Text] [Related]
7. Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials.
Roman-Gonzalez A; Jimenez C
Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):174-183. PubMed ID: 28234804
[TBL] [Abstract][Full Text] [Related]
8. High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease.
Jimenez C; Núñez R; Wendt R
Curr Opin Endocrinol Diabetes Obes; 2020 Jun; 27(3):162-169. PubMed ID: 32250976
[TBL] [Abstract][Full Text] [Related]
9. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
Plouin PF; Fitzgerald P; Rich T; Ayala-Ramirez M; Perrier ND; Baudin E; Jimenez C
Horm Metab Res; 2012 May; 44(5):390-9. PubMed ID: 22314389
[TBL] [Abstract][Full Text] [Related]
10. Pheochromocytomas and Paragangliomas.
Tevosian SG; Ghayee HK
Endocrinol Metab Clin North Am; 2019 Dec; 48(4):727-750. PubMed ID: 31655773
[TBL] [Abstract][Full Text] [Related]
11. Pheochromocytoma: a review.
Tsirlin A; Oo Y; Sharma R; Kansara A; Gliwa A; Banerji MA
Maturitas; 2014 Mar; 77(3):229-38. PubMed ID: 24472290
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapies for pheochromocytoma and paraganglioma.
Jimenez C; Fazeli S; Román-Gonzalez A
Endocr Relat Cancer; 2020 Jul; 27(7):R239-R254. PubMed ID: 32369773
[TBL] [Abstract][Full Text] [Related]
13. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
[TBL] [Abstract][Full Text] [Related]
14. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.
Strosberg JR
Semin Oncol; 2013 Feb; 40(1):120-33. PubMed ID: 23391119
[TBL] [Abstract][Full Text] [Related]
15. The management of benign and malignant pheochromocytoma and abdominal paraganglioma.
Edström Elder E; Hjelm Skog AL; Höög A; Hamberger B
Eur J Surg Oncol; 2003 Apr; 29(3):278-83. PubMed ID: 12657240
[TBL] [Abstract][Full Text] [Related]
16. Pheochromocytomas and paragangliomas in humans and dogs.
Galac S; Korpershoek E
Vet Comp Oncol; 2017 Dec; 15(4):1158-1170. PubMed ID: 28120550
[TBL] [Abstract][Full Text] [Related]
17. Metastatic pheochromocytoma and paraganglioma.
Angelousi A; Kassi E; Zografos G; Kaltsas G
Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
[TBL] [Abstract][Full Text] [Related]
18. [Pheochromocytoma and paraganglioma: basics for the general practitioner].
Loosli N; Köhler BB; Pechère-Bertschi A; Karenovics W; Triponex F
Rev Med Suisse; 2014 Sep; 10(441):1650-2, 1654-5. PubMed ID: 25322623
[TBL] [Abstract][Full Text] [Related]
19. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma.
Fishbein L; Del Rivero J; Else T; Howe JR; Asa SL; Cohen DL; Dahia PLM; Fraker DL; Goodman KA; Hope TA; Kunz PL; Perez K; Perrier ND; Pryma DA; Ryder M; Sasson AR; Soulen MC; Jimenez C
Pancreas; 2021 Apr; 50(4):469-493. PubMed ID: 33939658
[TBL] [Abstract][Full Text] [Related]
20. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L; Habra MA; Jiménez C
Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
